Literature DB >> 28842450

Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.

Silvia Rossi1, Valeria Studer1, Caterina Motta1, Serena Polidoro1, Jacopo Perugini2, Giulia Macchiarulo1, Ambra Mara Giovannetti1, Lorena Pareja-Gutierrez1, Andrea Calò1, Isabella Colonna1, Roberto Furlan1, Gianvito Martino1, Diego Centonze1.   

Abstract

OBJECTIVE: To explore the inflammatory processes in the pathogenesis of psychiatric symptoms and the prognostic value of psychiatric comorbidities in multiple sclerosis (MS).
METHODS: Four hundred five patients with relapsing-remitting (RR) MS underwent psychiatric evaluation by means of Beck Depression Inventory II (BDI-II) and State/Trait Anxiety Inventory (STAI-Y). The inflammatory activity level was assessed by MRI. In a subset of 111 treatment-naive patients, CSF levels of proinflammatory cytokines were determined. Correlation and regression analyses were performed to determine associations between variables.
RESULTS: Relapsing patients demonstrated greater values of STAI-state and BDI-II compared with remitting patients but comparable trait-anxiety scores. There were no significant differences in psychometric parameters between relapsing and asymptomatic MRI-active patients, highlighting the effect of subclinical inflammation on mood disturbances. A significant reduction of STAI-state and BDI-II scores was recorded, along with the subsiding of neuroinflammation. Interleukin-2 CSF levels were found to correlate with STAI-state, while tumor necrosis factor-α and interleukin-1β correlated with BDI-II. Because emotional disorders were associated with subclinical inflammation, variations of the psychometric profile were able to detect subclinical reactivation earlier. In line with this, high STAI-state values considerably predicted the possibility of disease reactivation.
CONCLUSIONS: Mood alterations are induced by intrathecal inflammation, even though not clinically apparent, and are able to predict inflammatory reactivations in RRMS. Inflammation is therefore a biological event, not less important than the traditional psychosocial factors, involved in mood disorders.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28842450     DOI: 10.1212/WNL.0000000000004411

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

Review 1.  Imaging and depression in multiple sclerosis: a historical perspective.

Authors:  Fabio Giuseppe Masuccio; Giulia Gamberini; Massimiliano Calabrese; Claudio Solaro
Journal:  Neurol Sci       Date:  2021-01-07       Impact factor: 3.307

2.  Multiple sclerosis: Intrathecal inflammation mediates mood in relapsing-remitting multiple sclerosis.

Authors:  Mitesh Patel
Journal:  Nat Rev Neurol       Date:  2017-09-15       Impact factor: 42.937

Review 3.  Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders.

Authors:  Amir Abdoli; Hoda Mirzaian Ardakani
Journal:  Metab Brain Dis       Date:  2019-07-27       Impact factor: 3.584

4.  Evidence of an antidepressant-like effect of xylopic acid mediated by serotonergic mechanisms.

Authors:  Robert Peter Biney; Charles Kwaku Benneh; Donatus Wewura Adongo; Elvis Ofori Ameyaw; Eric Woode
Journal:  Psychopharmacology (Berl)       Date:  2021-04-10       Impact factor: 4.530

Review 5.  Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research.

Authors:  Kristen Davies; Emma Dures; Wan-Fai Ng
Journal:  Nat Rev Rheumatol       Date:  2021-10-01       Impact factor: 20.543

Review 6.  Neuroinflammation in HIV-associated depression: evidence and future perspectives.

Authors:  Arish Mudra Rakshasa-Loots; Heather C Whalley; Jaime H Vera; Simon R Cox
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 13.437

7.  Socioeconomic status and race are correlated with affective symptoms in multiple sclerosis.

Authors:  Yujie Wang; Fan Tian; Kathryn C Fitzgerald; Jagriti Jackie Bhattarai; Robert T Naismith; Megan Hyland; Peter A Calabresi; Ellen M Mowry
Journal:  Mult Scler Relat Disord       Date:  2020-02-14       Impact factor: 4.339

Review 8.  Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis.

Authors:  Giulia Menculini; Elena Chipi; Federico Paolini Paoletti; Lorenzo Gaetani; Pasquale Nigro; Simone Simoni; Andrea Mancini; Nicola Tambasco; Massimiliano Di Filippo; Alfonso Tortorella; Lucilla Parnetti
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

9.  Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Xin Wu; Tao Xue; Zilan Wang; Zhouqing Chen; Xuwei Zhang; Wei Zhang; Zhong Wang
Journal:  Front Pharmacol       Date:  2021-05-17       Impact factor: 5.810

10.  Immunomodulation Eliminates Inflammation in the Hippocampus in Experimental Autoimmune Encephalomyelitis, but Does Not Ameliorate Anxiety-Like Behavior.

Authors:  Pece Kocovski; Nuzhat Tabassum-Sheikh; Stephanie Marinis; Phuc T Dang; Matthew W Hale; Jacqueline M Orian
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.